Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Locally Advanced OsteosarcomaMetastatic OsteosarcomaRecurrent OsteosarcomaRefractory OsteosarcomaUnresectable Osteosarcoma

Interventions

BIOLOGICAL

Atezolizumab

Given IV

DRUG

Cabozantinib

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER